

Advent Pharma Ltd.
Statement of Financial Position (Un-audited)
As at March 31, 2022

Particulars	Notes	Amount in Taka	
		31-Mar-2022	30-Jun-2021
ASSETS			
NON-CURRENT ASSETS		1,381,497,008	1,257,626,287
Property, Plant & Equipment	4.00	1,197,918,848	1,227,902,159
Capital Work in Progress (Building Construction)	5.00	183,578,160	29,724,128
Right of use Assets		-	437,124
CURRENT ASSETS		231,709,105	261,979,334
Inventories	6.00	70,358,930	75,411,909
Trade and Other Receivable		119,732,456	114,021,998
Advances, Deposits and Pre-payments		40,340,703	29,856,397
Investment in FDR	7.00	-	40,000,000
Cash and Cash Equivalents	8.00	1,277,016	2,689,030
Total Assets		1,613,206,113	1,520,042,745
SHAREHOLDERS' EQUITY AND LIABILITIES			
SHAREHOLDERS' EQUITY		1,305,797,041	1,234,180,120
Share Capital	9.00	931,327,320	913,066,000
Retained Earnings	10.00	374,469,721	321,114,120
NON-CURRENT LIABILITIES		137,963,772	133,550,170
Long Term Borrowings - Net of Current Portion		12,123,315	14,561,946
Deferred Tax Liabilities	11.00	125,840,457	118,988,224
Liabilities for lease net current maturity	14.00	-	-
CURRENT LIABILITIES		169,445,300	152,312,455
Current Portion of Long Term Borrowings		7,912,963	7,912,963
Payable to IPO Applicants		104,355	109,355
Short Term Borrowings		35,064,309	36,826,566
Trade and other payables		7,838,061	8,917,226
Unclaimed Dividend Account	12.00	-	3,681,708
Dividend Payable	13.00	2,610,480	2,868,779
Liabilities for Lease-current maturity	14.00	114,999	607,545
Liabilities for expenses		5,208,942	8,468,549
Liability for contribution to WPPF		38,938,738	30,508,761
Provision for Current Tax	15.00	71,652,453	52,411,003
Total Liabilities		307,409,073	285,862,625
Total Shareholders' Equity and Liabilities		1,613,206,113	1,520,042,745
Net Asset Value (NAV) per Share	24.00	14.02	13.52


Company Secretary


Chief Financial Officer


Director


Managing Director


Chairman

Dated: April 28, 2022
Place: Dhaka

Advent Pharma Ltd.
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period from July 01, 2021 to March 31, 2022

Particulars	Notes	Amount in Taka		Amount in Taka	
		July 01, 2021 to March 31, 2022	July 01, 2020 to March 31, 2021	Jan 01, 2022 to March 31, 2022	Jan 01, 2021 to March 31, 2021
A Revenues	0.00	410,640,591	387,931,760	145,132,778	126,008,710
B Cost of Sales	16.00	(233,171,619)	(214,437,965)	(83,662,440)	(76,845,418)
C Gross Profit		177,468,972	173,493,795	61,470,338	49,163,292
Operating Expenses		(51,298,534)	(39,365,351)	(22,245,897)	(19,237,612)
D Administrative expenses	18.00	(19,822,727)	(15,721,896)	(8,836,800)	(7,815,947)
Selling & Marketing Expenses	19.00	(31,475,807)	(23,643,455)	(13,409,097)	(11,421,665)
E Operating Profit		126,170,438	134,128,444	39,224,441	29,925,680
Non Operating Expenses		(5,688,678)	(5,270,241)	(2,103,917)	(1,809,014)
F Financial Expenses	20.00	(5,688,678)	(5,270,241)	(2,103,917)	(1,809,014)
G Other Income	21.00	1,288,760	3,191,867	71,538	1,304,674
H Loss on Disposal of Fixed Assets	22.00	-	(388,448)	-	(388,448)
I Profit Before W.P.P.F		121,770,520	131,661,621	37,192,062	29,032,892
J Expenses for W.P.P.F		(5,798,596)	(6,269,601)	(1,771,051)	(1,382,519)
K Profit Before Tax		115,971,924	125,392,020	35,421,011	27,650,374
L Income Tax Expenses		(26,093,683)	(32,136,385)	(7,969,728)	(6,863,643)
Current Tax	15.00	(19,241,450)	(15,232,460)	(5,684,881)	(1,266,142)
Deferred Tax	11.00	(6,852,233)	(16,903,925)	(2,284,847)	(5,597,500)
M Net Profit After Tax		89,878,241	93,255,635	27,451,283	20,786,731
N Other Comprehensive Income		-	-	-	-
O Total Comprehensive income		89,878,241	93,255,635	27,451,283	20,786,731
P Basic Earnings per Share (EPS)		0.97	1.00	0.29	0.22


Company Secretary


Chief Financial Officer


Director


Managing Director


Chairman

Dated: April 28, 2022
Place: Dhaka

Advent Pharma Ltd.
Statement of Changes in Equity (Un-audited)
For the Period from July 01, 2021 to March 31, 2022

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2021	913,066,000	321,114,120	1,234,180,120
Net Profit for the period	-	89,878,241	89,878,241
Stock Dividend (2020-2021)	18,261,320	(18,261,320)	-
Cash Dividend (2020-2021)	-	(18,261,320)	(18,261,320)
Balance as on March 31, 2022	931,327,320	374,469,721	1,305,797,041

Advent Pharma Ltd.
Statement of Changes in Equity(Un-audited)
For the Period from July 01, 2020 to March 31, 2021

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2020	830,060,000	290,530,279	1,120,590,279
Net Profit for the period	-	93,255,635	93,255,635
Stock Dividend (2019-2020)	83,006,000	(83,006,000)	-
Balance as on March 31, 2021	913,066,000	300,779,914	1,213,845,914



Company Secretary



Chief Financial Officer



Director



Managing Director



Chairman

Dated: April 28, 2022

Place: Dhaka

Advent Pharma Ltd.
Statement of Cash Flows (Un-audited)
For the Period from July 01, 2021 to March 31, 2022

Particulars	Amount in Taka	
	July 01, 2021	July 01, 2020
	to	to
	March 31, 2022	March 31, 2021

A. CASH FLOWS FROM OPERATING ACTIVITIES:

Cash Receipts from Customers & Others	406,218,893	400,029,469
Cash Paid to Suppliers	(196,079,086)	(187,082,757)
Cash paid to Employees	(32,135,248)	(28,053,312)
Cash paid to Others	(31,326,815)	(20,167,420)
Tax Paid During This period	(1,549,895)	(3,189,945)
Net cash generated from operating activities	145,127,849	161,536,035

B. CASH FLOWS FROM INVESTING ACTIVITIES:

Paid for Acquisition of Property, Plant & Equipment	(435,195)	(602,340)
Paid for Capital Work -in- Progress (construction)	(153,590,932)	(163,337,816)
Investment in FDR	40,000,000	-
Proceeds from disposal of Fixed Assets	-	230,000
Net cash used for investing activities	(114,026,127)	(163,710,156)

C. CASH FLOWS FROM FINANCING ACTIVITIES:

Net Received/Payment of Short Term Borrowings	(1,762,257)	13,468,490
Net Received/Payment of Long Term Borrowings	(2,438,631)	(1,954,229)
Financial Expenses Paid	(5,589,021)	(2,981,456)
Cash dividend paid	(22,201,327)	(8,079,122)
Lease Payment	(517,500)	(517,500)
Refund to IPO Applicants	(5,000)	-
Net cash provided by financing activities	(32,513,736)	(63,817)

D. Net Increase/(Decrease) in Cash & Cash equivalents (A+B+C)

(1,412,014)	(2,237,937)
--------------------	--------------------

E. Cash & Cash equivalents at the beginning of the period

2,689,030	6,338,662
------------------	------------------

F. Cash & Cash equivalents at the end of the period (D+E)

1,277,016	4,100,725
------------------	------------------

G. Net Operating Cash Flow Per Share


1.56

1.73


Company Secretary


Chief Financial Officer


Director


Managing Director


Chairman

Dated: April 28, 2022

Place: Dhaka

Advent Pharma Limited

Notes, comprising a summary of significant accounting policies and other explanatory information
as at and for the period ended 31 March-2022

1.00 Corporate History of the Reporting Entity

Advent Pharma Limited (The Company) was incorporated in Bangladesh as a Private Limited Company under The Companies Act, 1994 vide Registration No. C-65459(2951)/2007 dated 25th January, 2007. Subsequently the company was converted into Public Company Limited by share 07 May 2016. The registered office of the company and the factory is located at Plot # B50-54, BSCIC Industrial Estate, Dhamrai, Dhaka, Bangladesh.

2.00 Corporate Business

The Company is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid dosage forms. All products have duly been approved by Drug Administration Authority and Department of Live Stock respectively.

3.00 Basis of preparation and significant accounting policies

The financial statements of the company have been prepared on going concern assumption under historical cost convention, on accrual basis and in accordance with the International Accounting Standards (IASs), International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities Exchange Rules 1987 and other laws and regulations applicable for the company.

The following International Accounting Standards were applied for the preparation of the financial statements for the period.

IAS 1	Presentation of Financial Statements
IAS 2	Inventories
IAS 7	Statement of Cash Flows
IAS 8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS 10	Events after the Reporting Period
IAS 12	Income Taxes
IAS 16	Property, Plant & Equipment
IAS 19	Employee Benefits
IAS 23	Borrowing Costs
IAS 24	Related Party Disclosures
IAS 32	Financial Instruments: Presentation
IAS 33	Earnings per Share
IAS 34	Interim Financial Reporting
IAS 36	Impairment of Assets
IAS 37	Provisions, Contingent Liabilities and Contingent Assets
IFRS 7	Financial Instruments: Disclosures
IFRS 8	Operating Segments
IFRS 9	Financial Instruments
IFRS 15	Revenue from Contracts form Customers
IFRS 16	Leases



		Amount in Taka	
		31-Mar-2022	30-Jun-2021
4.00 Property, Plant and Equipment			
A. Cost			
Opening Balance		1,381,013,653	1,214,404,201
Add: Addition during the period		206,345	168,088,026
Less: Disposal during the period		-	(1,478,574)
		<u>1,381,219,998</u>	<u>1,381,013,653</u>
B. Accumulated Depreciation			
Opening Balance		153,111,494	115,803,056
Add: Depreciation charged during the period		30,189,656	38,168,564
Less: Adjustment during the period		-	(860,126)
		<u>183,301,150</u>	<u>153,111,494</u>
Written down Value (A-B)		<u>1,197,918,848</u>	<u>1,227,902,159</u>
<i>Details are shown in Annexure-A.</i>			
5.00 Capital Work In Progress (Building Construction)			
Opening Balance		29,724,128	5,924,163
Addition during the period		153,854,032	190,117,421
Transfer to Factory Building		-	(166,317,456)
Closing Balance		<u>183,578,160</u>	<u>29,724,128</u>
6.00 Inventories			
Finished Goods (Note-16.00)		33,641,008	32,626,808
Raw Materials		20,245,303	25,746,190
Packing Materials		5,296,125	6,430,426
Spare Parts		73,249	84,135
Work In Process (Note-16.00)		11,103,245	10,524,350
		<u>70,358,930</u>	<u>75,411,909</u>
7.00 Investment in FDR			
<u>Name of Financial Institution</u>			
Midland Bank Ltd.	FDR No.: 0019761	-	40,000,000
Total		<u>-</u>	<u>40,000,000</u>
8.00 Cash & Cash Equivalents			
Cash in hand (Note-8.01)		86,986	356,016
Cash at bank (Note-8.02)		1,190,030	2,333,014
Total		<u>1,277,016</u>	<u>2,689,030</u>
8.01 Cash in Hand			
Head Office		72,901	304,744
Depots		14,085	51,272
		<u>86,986</u>	<u>356,016</u>
Cash in hand has been certified by the management of the company.			
8.02 Cash at Bank (Note -8.02.01)		<u>1,190,030</u>	<u>2,333,014</u>
8.02.01 Cash at Bank			
<u>Bank Name</u>			
Islami Bank Bangladesh Ltd.	A/C No. # 283517	147,920	245,707
Dutch Bangla Bank Ltd.	A/C No. # 129775	157,485	1,597,505
Janata Bank Ltd	A/C No. # 10035785	117,619	101,998
IFIC Bank Ltd.	A/C No. # 327-041	102,701	65,053
IFIC Bank Ltd.	A/C No. # 327-001	126,554	49,212
IFIC Bank Ltd.	A/C No. # 327-003	118,284	56,475
Shahjalal Islami Bank Ltd.	A/C No. # 000-7339	106,298	18,545
Midland Bank Ltd.	A/C No. # 000-6230	140,146	18,574
BRAC Bank Ltd.	A/C No. # 150001	94,051	95,973
BRAC Bank Ltd.	A/C No. # 150002	78,972	83,972
Total		<u>1,190,030</u>	<u>2,333,014</u>
9.00 Share Capital			
<u>Authorized Capital :</u>			
100,000,000 ordinary shares of Tk. 10.00 each		<u>1,000,000,000</u>	<u>1,000,000,000</u>
<u>Issued, Subscribed & Paid-up Capital :</u>			
913,06,600 ordinary shares of Tk. 10.00 each		<u>931,327,320</u>	<u>913,066,000</u>
931,32,732 ordinary shares of Tk. 10.00 each			



Share holding position of Shareholders:

Category of Shareholders	Number of Share Holding		Percentage of Share Holding		Amount in Taka	
	31-Mar-2022	30-Jun-2021	31-Mar-2022	30-Jun-2021	31-Mar-2022	30-Jun-2021
Director & Sponsor	27,957,751	28,706,342	30.02%	31.44%	279,577,510	287,063,420
Institutional	24,323,182	17,225,306	26.12%	18.87%	243,231,820	172,253,060
Public	40,851,799	45,374,952	43.86%	49.70%	408,517,990	453,749,520
Total	93,132,732	91,306,600	100.00%	100.00%	931,327,320	913,066,000

10.00 Retained Earnings

Balance brought forward	321,114,120	290,530,279
Add: Profit for the period	89,878,241	113,589,841
Stock Dividend	(18,261,320)	(83,006,000)
Cash Dividend Payable	(18,261,320)	-
Balance carried forward	374,469,721	321,114,120

11.00 Deferred Tax Liabilities

Opening Balance	118,988,224	101,428,244
Add: Provision made during the period (Note-11.01)	6,852,233	17,559,980
Closing Balance	125,840,457	118,988,224

11.01 Deferred tax liabilities as at March 31, 2022 is arrived as follows :

Written Down Value of PPE as per Accounting Base	1,197,918,848	1,227,902,159
Written Down Value as per Third Schedule	(638,627,927)	(699,065,607)
Net Temporary Difference	559,290,921	528,836,552
Income Tax Rate	22.50%	22.50%
Deferred Tax Liability	125,840,457	118,988,224
Opening Deferred Tax Liability	(118,988,224)	(101,428,244)
Deferred Tax Expenses	6,852,233	17,559,980

12.00 Unclaimed Dividend Account:

Dividend payable (2017-2018)	-	3,681,708
Total	-	3,681,708

13.00 Dividend Payable:

Dividend payable (2020-2021)	1,000,126	-
Dividend payable (2019-2020)	2,084	2,084
Dividend payable (2018-2019)	1,608,270	2,866,695
Total	2,610,480	2,868,779

14.00 Liability for Leases net of current Maturity:

Beginning Balance	607,545	1,141,776
Add: Interest Expenses	24,954	98,269
Less: Payment	(517,500)	(632,500)
Closing Balance	114,999	607,545
Less: Liabilities for lease-current maturity	(114,999)	(607,545)
Total	-	-

15.00 Provision for Current Tax

Opening Balance	52,411,003	49,369,509
Add: Provision for tax during the period (Note-15.01)	19,241,450	3,041,494
Total	71,652,453	52,411,003

15.01 Provision for Tax during the period

(A) Regular

Accounting Profit before Tax	115,971,924	134,191,315
Add: Other Inadmissible Allowances		
Accounting Depreciation	30,189,656	38,168,564
Other Income	(1,288,760)	(11,809,104)
Less: Items for Separate Consideration		
Depreciation as per 3rd Schedule	(60,644,025)	(161,474,538)
Total Taxable Income	84,228,795	(923,763)
Rate	22.50%	22.50%
Total Tax Expenses/Current Tax	18,951,479	(207,847)
Tax on other income	289,971	2,657,048
Total Tax Payable	19,241,450	2,449,201

(B) Minimum Tax

Revenue from sales	403,764,918	495,106,639
Other Income	8,164,432	11,809,104
Total Revenue	411,929,350	506,915,743
Rate of Tax	0.60%	0.60%
Minimum Tax	2,471,576	3,041,494

(C) Advance Tax

	1,549,895	2,397,065
Provision for the year (Whichever is Higher)	19,241,450	3,041,494



16.00 Cost of Sales

	Nine Months Ended		3rd Quarter Ended	
	July 01, 2021 to Mar. 31, 2022	July 01, 2020 to Mar. 31, 2021	Jan 01, 2022 to Mar. 31, 2022	Jan 01, 2021 to Mar. 31, 2021
Raw Materials Consumed	185,364,774	174,962,744	66,103,764	59,629,637
Manufacturing Overhead (Note-17.00)	50,514,396	46,613,645	17,211,779	16,328,259
	235,879,170	221,576,388	83,315,543	75,957,896
Add: Opening Work in process	10,524,350	14,402,451	9,007,825	10,207,825
Less: Closing Work in process	(11,103,245)	(9,527,825)	(11,103,245)	(9,527,825)
Cost of Goods manufactured	235,300,275	226,451,014	81,220,123	76,637,896
Add: Opening stock of finished Goods	32,626,808	24,923,097	36,527,450	36,527,450
Cost of Goods Available for Sale	267,927,083	251,374,111	117,747,573	113,165,346
Less: Closing stock of finished Goods	(33,641,008)	(36,005,352)	(33,641,008)	(36,005,352)
Less: Sample Distribution	(1,114,456)	(930,794)	(444,125)	(314,576)
Cost of Sales	233,171,619	214,437,965	83,662,440	76,845,418

17.00 Manufacturing Overhead

Wages and Salary	8,466,917	7,880,821	2,898,330	2,930,325
Festival Bonus	426,900	238,388	-	-
Overtime	633,093	579,631	280,080	300,115
Packaging Materials Consumed	7,643,306	6,842,594	2,735,649	2,382,425
Spare Parts Consumed	636,174	655,463	282,221	294,033
Repair & Maintenance	472,470	711,985	275,064	488,164
Electricity Bill (Factory)	974,617	1,194,290	262,658	333,711
Disel & Fuel	119,300	152,295	48,800	47,125
Electric & Sanitary Goods	234,433	50,316	147,306	14,290
Fire Insurance Premium	149,927	130,577	53,202	43,527
Canteen Expenses	1,457,190	1,026,915	446,962	441,171
Laboratory Expenses	85,062	38,440	42,562	24,190
Cleaning & Washing	74,235	49,962	22,190	17,207
Internet bill	24,260	31,050	7,500	7,500
Mobile & Telephone bill	25,775	27,350	8,325	9,300
Uniform	94,985	93,520	35,565	24,760
Depreciation (Annexure-A)	28,995,752	26,910,048	9,665,365	8,970,416
Total	50,514,396	46,613,644	17,211,779	16,328,259

18.00 Administrative Expenses

Salary & Allowance	7,471,500	6,696,683	2,873,500	2,569,750
Director Remuneration (Note # 44.01)	900,000	900,000	300,000	300,000
Conveyance	76,945	103,769	20,390	35,480
Subscription, Gift & Donation	277,220	50,160	35,170	19,250
Festival Bonus	299,125	148,375	-	-
Board meeting attendance fees (Note # 44.01)	225,000	225,000	45,000	45,000
Cleaning & Sanitation	62,374	65,771	23,538	40,532
Credit Rating Fee	50,000	50,000	50,000	-
Electricity Bill	144,835	160,097	32,175	37,521
Entertainment	312,943	215,071	158,726	102,525
Garage Rent	16,200	16,200	5,400	5,400
Legal, License & Renewal & Professional fee	1,763,490	1,931,638	1,211,409	1,612,692
Research & Product Development	1,778,362	506,915	1,275,462	502,415
Miscellaneous Expense	2,253,896	1,042,487	958,435	784,197
Newspaper & Magazine	2,150	1,000	780	750
Postage, Stamps & Courier	13,280	31,594	5,280	15,470
Printing & Stationery	325,714	347,726	234,570	260,380
Office Maintenance	384,200	190,105	252,170	102,535
Training Allowance	-	32,000	-	32,000
Vehicle Repair & Maintenance	503,285	436,245	411,030	405,200
Fuel & Gas	568,201	205,115	283,784	78,863
Telephone & Mobile	105,285	130,482	26,300	30,500
Internet bill	81,000	81,000	27,000	27,000
Annual General Meeting Expenses	379,240	228,420	-	180,000
Audit Fees Including VAT	172,500	201,250	57,500	57,500
Interest expenses on the Lease Liability	24,954	80,390	3,393	22,426
Depreciation Charge for the Right-of-Use Asset	437,124	437,123	145,708	145,707
Depreciation (Annexure-A)	1,193,904	1,207,280	400,080	402,854
Total	19,822,727	15,721,896	8,836,800	7,815,947



19.00 Selling & Marketing Expenses

Salary & Allowance
 Travelling & Conveyance
 Festival Bonus
 Advertisement
 Marketing Promotion
 Distribution Cost
 Sample Distribution
Total

Nine Months Ended		3rd Quarter Ended	
July 01, 2021 to Mar. 31, 2022	July 01, 2020 to Mar. 31, 2021	Jan 01, 2022 to Mar. 31, 2022	Jan 01, 2021 to Mar. 31, 2021
13,152,038	11,402,431	4,741,753	4,691,297
4,468,025	3,140,815	2,490,055	1,748,015
382,485	224,158	-	-
150,554	122,050	58,812	30,250
5,032,331	2,324,498	2,275,020	1,860,999
7,175,918	5,498,709	3,399,332	2,776,528
1,114,456	930,794	444,125	314,576
31,475,807	23,643,455	13,409,097	11,421,665

20.00 Financial Expenses

Bank Charges
 Interest on Loan
 Interest on W.P.P.F Fund Used
Total

279,985	230,675	47,584	46,923
2,777,312	3,598,808	1,179,206	1,281,839
2,631,381	1,440,758	877,127	480,252
5,688,678	5,270,241	2,103,917	1,809,014

21.00 Other Income

Interest on FDR
 Bank Interest
 Sales of Wastage (Others)
 Toll manufacturing Income
Total

1,050,000	2,900,000	-	1,200,000
38,727	33,600	-	-
200,033	258,266	71,538	104,674
-	-	-	-
1,288,760	3,191,867	71,538	1,304,674

22.00 Other Loss

Loss on Disposal of Fixed Assets

-	388,448	-	388,448
-	388,448	-	388,448



23.00 Basic Earnings Per Share

Profit after tax
Weighted average number of ordinary shares outstanding
Basic Earnings per share

Nine Month Ended Product		Quarterly Product	
31-Mar-2022	31-Mar-2021	31-Mar-2022	31-Mar-2021
89,878,241	93,255,635	27,451,283	20,786,731
93,132,732	93,132,732	93,132,732	93,132,732
0.97	1.00	0.29	0.22

As there are no shares under option, Basic & Diluted earnings per share are same for the period. This has been calculated in compliance with the requirements of IAS 33 Earnings per share. EPS is the basic earnings dividing by the weighted average number of ordinary shares outstanding at the end of

23.01 Calculation of Weighted Average Number of Shares as on March 31, 2022

Particulars	Share Numbers	Outstanding Period	Length in Days	Daily Product	Nine Month Ended Product (Weighted Average)	Quarterly Product (Weighted Average)
					31-Mar-2022	31-Mar-2022
Shares at beginning	91,306,600	July-21 to Mar-22	274	25,018,008,400	91,306,600	91,306,600
Stock Dividend @ 2%	1,826,132	July-21 to Mar-22	274	500,360,168	1,826,132	1,826,132
Total	93,132,732			25,518,368,568	93,132,732	93,132,732

23.02 Calculation of Weighted Average Number of Shares as on March 31, 2021

Particulars	Share Numbers	Outstanding Period	Length in Days	Daily Product	Nine Month Ended Product (Weighted Average)	Quarterly Product (Weighted Average)
					31-Mar-2021	31-Mar-2021
Shares at beginning	83,006,000	July-20 to Mar-21	274	22,743,644,000	83,006,000	83,006,000
Stock Dividend @ 10% -2020	8,300,600	July-20 to Mar-21	274	2,274,364,400	8,300,600	8,300,600
Stock Dividend @ 2% -2021	1,826,132	July-20 to Mar-21	274	500,360,168	1,826,132	1,826,132
Total	93,132,732			25,518,368,568	93,132,732	93,132,732

24.00 Net Asset Value (NAV) per Share

Total Asset
Less: Total outside Liability
Net Asset
Number of ordinary shares outstanding
Net Assets Value (NAV) per Share

31-Mar-2021	30-Jun-2021
1,613,206,113	1,520,042,745
307,409,073	285,862,625
1,305,797,040	1,234,180,120
93,132,732	91,306,600
14.02	13.52

25.00 Net Operating Cash Flows per Share (NOCFPS)

Net Cash Generated From Operating Activities
Weighting Average Number of Shares Outstanding
Net Operating Cash Flows per Share (NOCFPS)

31-Mar-2021	31-Mar-2021
145,127,849	161,536,035
93,132,732	93,132,732
1.56	1.73

26.00 Reconciliation of Net Profit with cash flows from Operating Activities:

Profit before Tax
Adjustment for:
Depreciation on property, plant and equipment
Adjustment for depreciation of the Right Use of Assets
Interest expenses on Lease
Financial Expenses
Loss on disposal of Fixed Assets

(Increase)/Decrease in Accounts Receivable
(Increase)/Decrease in Inventory
Less: Increase/(Decrease) in Trade and Other Payables
Add: Decrease/(Increase) in Advance, Deposit & Prepayments
Add: Increase in Liabilities for Expenses
Add: Increase in Liability for contribution to W.P.P.F

Less: Income Tax Paid
Net Cash Generated from Operating Activities

31-Mar-2021	31-Mar-2020
115,971,924	125,392,020
30,189,656	28,117,328
437,124	437,123
24,954	80,390
5,688,678	5,270,241
-	388,448
152,312,336	159,685,551
(5,710,458)	8,905,843
5,052,979	(10,042,294)
(1,113,415)	(741,783)
(8,934,411)	618,738
(727,883)	30,326
5,798,596	6,269,600
146,677,744	164,725,980
(1,549,895)	(3,189,945)
145,127,849	161,536,035



27.00 Related parties Transaction:

As per IAS 24 Related Party Disclosures, Parties are considered to be related if one of the party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decision.

27.01 As per paragraph 17 of IAS 24 : Disclosure of key management personnel compensation.**a) Short-term employee benefits :**

The amount of transaction for remuneration and board meeting fee during the period from 1st July 2021 to 31 st March 2022 are as follows:

Name	Designation	Remuneration	Board meeting fee
A.K.M. Shafiqul Alam	Chairman	-	25,000
Faria Binta Alam	Managing Director	900,000	25,000
Wajhi Ahmed	Director	-	25,000
Kazi Rina Alam	Director	-	25,000
Md. Tazul Islam	Director	-	25,000
Mohammad Towhidul Islam	Nominee Director	-	25,000
Asif Iqbal Chowdhury	Nominee Director	-	25,000
Mohammed Salim	Independent Director	-	25,000
Shekh Karimuzzaman	Independent Director	-	25,000
Total		900,000	225,000

b) Post employment benefits: Nil

c) Other long term benefits: Nil

d) Termination benefits: Nil

e) Share-based payment: Nil

28.00 Significant Deviation

Advent Pharma Ltd. is a veterinary medicine producer. During the period our sales has increased comparative to previous period but increased operating expenses. As a result net profit after tax and earnings per share has decreased and net operating cash flow per share has decreased due to increase of accounts receivable comparative to previous period and also increase of cash paid to suppliers, employees and others proportionately from the previous period.



Advent Pharma Ltd.
Schedule of Property, Plant and Equipment
As at March 31, 2022

Annexure-A
(Amount in Taka)

Particulars	Cost			Depreciation				Written down value as on 31-March-2022
	Balance as on 01-July-2021	Addition during the Period	Disposal during the Period	Balance as on 31-March-2022	Rate of Dep.	Charged during the Period	Adjustment during the Period	Balance as on 31-March-2022
Land	3,783,816	-	-	3,783,816	0%	-	-	3,783,816
Land Development	9,454,530	-	-	9,454,530	2.5%	158,196	-	8,278,949
Factory Building	925,159,750	-	-	925,159,750	2.5%	16,348,446	-	855,568,697
Plant & Machinery	273,073,384	20,150	-	273,093,534	5%	8,168,446	-	209,667,665
Sub-Station	6,694,722	-	-	6,694,722	10%	269,219	-	3,320,372
Motor Vehicle	6,158,982	-	-	6,158,982	15%	383,049	-	3,021,835
Furniture & Fixture	8,126,555	101,895	-	8,228,450	10%	386,809	-	4,835,426
Solar Panel	2,004,740	-	-	2,004,740	10%	83,946	-	1,035,339
Generator	627,520	-	-	627,520	10%	19,603	-	241,770
Air Conditioner	4,254,120	-	-	4,254,120	5%	120,032	-	3,080,823
Office Equipment	6,501,413	81,100	-	6,582,513	10%	304,014	-	3,796,961
HVAC System	44,536,240	-	-	44,536,240	5%	1,297,967	-	33,314,473
Laboratory Equipment	51,378,630	3,200	-	51,381,830	5%	1,500,195	-	38,507,497
Product Development Equipment	20,725,781	-	-	20,725,781	5%	606,042	-	15,555,086
ETP	18,488,470	-	-	18,488,470	5%	541,182	-	13,890,334
Books & Journals	45,000	-	-	45,000	15%	2,510	-	19,805
total	1,381,013,653	206,345	-	1,381,219,998		30,189,656	-	1,197,918,848

Allocation of Depreciation:

Administrative cost	1,193,904
Factory cost	28,995,752
Total	30,189,656



Advent Pharma Ltd.
Schedule of Property, Plant and Equipment
As at March 31, 2021

Annexure-A
(Amount in Taka)

Particulars	Cost			Depreciation					Written down value as on 31-Mar-2021
	Balance as on 01-July-2020	Addition during the period	Disposal during the period	Balance as on 31-Mar-2021	Rate of Dep.	Balance as on 01-July-2020	Charged during the period	Adjustment during the period	Balance as on 31-Mar-2021
Land	3,783,816	-	-	3,783,816	0%	-	-	-	3,783,816
Land Development	9,454,530	-	-	9,454,530	2.5%	801,048	162,253	-	963,301
Factory Building	758,842,294	-	-	758,842,294	2.5%	34,439,549	13,582,551	-	48,022,100
Plant & Machinery	273,035,384	38,000	-	273,073,384	5%	43,794,758	8,596,682	-	52,391,440
Sub-Station	6,694,722	-	-	6,694,722	10%	2,706,287	299,133	-	3,005,420
Motor Vehicle	6,097,576	1,539,980	1,478,574	6,158,982	15%	3,195,020	326,538	860,126	2,661,432
Furniture & Fixture	8,059,885	50,920	-	8,110,805	10%	2,439,835	424,474	-	2,864,309
Solar Panel	2,004,740	-	-	2,004,740	10%	761,090	93,274	-	854,364
Generator	627,520	-	-	627,520	10%	337,106	21,781	-	358,887
Air Conditioner	4,254,120	-	-	4,254,120	5%	884,799	126,350	-	1,011,149
Office Equipment	6,431,313	16,100	-	6,447,413	10%	2,041,010	329,918	-	2,370,928
HVAC System	44,536,240	-	-	44,536,240	5%	8,102,093	1,366,281	-	9,468,374
Laboratory Equipment	51,322,810	55,820	-	51,378,630	5%	9,270,247	1,577,536	-	10,847,783
Product Development Equipment	20,725,781	-	-	20,725,781	5%	3,714,067	637,939	-	4,352,006
ETP	18,488,470	-	-	18,488,470	5%	3,297,400	569,665	-	3,867,065
Books & Journals	45,000	-	-	45,000	15%	18,747	2,953	-	21,700
Total	1,214,404,201	1,700,820	1,478,574	1,214,626,447		115,803,056	28,117,328	860,126	143,060,258
									1,071,566,189

Allocation of Depreciation:

Administrative cost	1,207,280
Factory cost	26,910,048
Total	28,117,328

